Ceftriaxone Market Size Worth USD 2.2 billion by 2031, Expanding at a CAGR of 2.9% | Exclusive Report by Transparency Market Research
August 18, 2023 08:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global ceftriaxone market is projected to flourish at a CAGR of 2.9% from 2022 to 2031....
Iterum Therapeutics Reports First Quarter 2020 Financial Results
May 14, 2020 06:45 ET
|
Iterum Therapeutics plc
--Phase 3 topline results from sulopenem clinical trials in uUTI and cUTI expected Q2 -- -- Raised $51.6 million through a private placement with new and existing investors -- DUBLIN,...
Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection
November 18, 2019 07:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
September 27, 2019 16:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
August 01, 2019 07:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics to Present Data on Uncomplicated Urinary Tract Infections at ASM Microbe 2019
June 21, 2019 07:30 ET
|
Iterum Therapeutics plc
Limited options remain for successful empiric treatment of uncomplicated urinary tract infections (uUTIs) in the community DUBLIN, Ireland and CHICAGO, June 21, 2019 (GLOBE NEWSWIRE) -- Iterum...
Iterum Therapeutics Reports First Quarter 2019 Financial Results
May 14, 2019 07:00 ET
|
Iterum Therapeutics plc
On track to complete enrollment in all three Phase 3 clinical trials before year-end Filed patent application that may extend Iterum’s intellectual property rights into the 2040s DUBLIN,...
Iterum Therapeutics Presents Data on Risks for Treatment Failure Associated with Uncomplicated Urinary Tract Infection and Activity of its Novel Antibiotic Sulopenem at ECCMID 2019
April 11, 2019 07:30 ET
|
Iterum Therapeutics plc
The highest risk of treatment failure is seen in patients previously infected with a resistant pathogen. Sulopenem has in vitro activity against isolates of Neisseria gonorrhoeae non-susceptible to...
Iterum to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
February 19, 2019 07:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant...
Iterum Therapeutics Presents Data Highlighting Antibiotic Sulopenem at IDWeek 2018
October 05, 2018 08:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant...